All articles

Making the full impact of a rare disease asset clear

Performing a risk assessment of the policy landscape and market trends to inform commercialization plan​

Developing a pre-launch roadmap ahead of launch for CGT rare disease asset​

Women's health

2026 midterm results create new opportunities in women’s health policy

Market and industry dynamics

White paper: Payment chain vs. supply chain–how they differ and why it matters

Drug pricing and affordability

OBBBA and Medicare negotiation eligibility: Considerations for manufacturers

Rare disease

What does payer-informed evidence generation for rare disease therapies look like?

Drug pricing and affordability

FFS vs. MA utilization will impact relative net prices in negotiation

Drug pricing and affordability

Differences in Part B and D pricing for IPAY 2028 drugs

Market and industry dynamics

How do Medicare Advantage and Medicare FFS utilization patterns differ?